In this cohort study of a large, diverse, commercially insured population, rates of SGLT2 inhibitor use for the treatment of patients with type 2 diabetes in the US increased from 2015 to 2019, yet rates remained low even among patients with type 2 diabetes and HFrEF, ASCVD, and CKD. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.